Leptin As an Adjunct of Insulin Therapy in Insulin-deficient Diabetes

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2003 Aug 21

PMID 12928770

Citations 20

Authors

F Miyanaga

Y Ogawa

K Ebihara

S Hidaka

T Tanaka

S Hayashi

H Masuzaki

K Nakao

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: The purpose of this study was to assess the therapeutic implication of leptin in insulin-deficient diabetes.

Methods: Insulin-deficient diabetes was induced by streptozotocin (STZ) in transgenic skinny mice overexpressing leptin. Plasma concentrations of glucose, insulin, and leptin were measured. The effects on body weight, food intake, and hypothalamic gene expressions were analyzed. After diabetes was induced, graded doses of insulin ranging from 0.4 to 51.2 mU.g(-1).day(-1) were injected. Co-administration of leptin and insulin was also carried out using osmotic pumps.

Results: After STZ injection, both transgenic and non-transgenic littermates developed marked hyperglycaemia as a result of severe hypoinsulinaemia [termed diabetic transgenic skinny mice overexpressing leptin (diabetic TGM) and diabetic non-transgenic littermates (diabetic WT) respectively], although diabetic TGM were more sensitive to exogenously administered insulin than diabetic WT. Diabetic WT were hypoleptinaemic and hyperphagic relative to non-diabetic WT, whereas diabetic TGM, which remained hyperleptinaemic, were less hyperphagic than diabetic WT. After STZ injection, hypothalamic expressions of orexigenic and anorexigenic peptide mRNAs were up-regulated and down-regulated, respectively, in diabetic WT, whereas they were unchanged in diabetic TGM. Diabetic TGM became normoglycaemic, when treated with insulin at such doses that did not improve hyperglycaemia in diabetic WT. We found that a sub-threshold dose of insulin that does not affect glucose homeostasis is effective in improving the diabetes in normal mice rendered diabetic by STZ injection, when combined with leptin.

Conclusions/interpretation: This study suggests that leptin could be used as an adjunct of insulin therapy in insulin-deficient diabetes, thereby providing an insight into the therapeutic implication of leptin as an anti-diabetic agent.

Citing Articles

Translational science: Newly emerging science in biology and medicine - Lessons from translational research on the natriuretic peptide family and leptin.

Nakao K Proc Jpn Acad Ser B Phys Biol Sci. 2019; 95(9):538-567.

PMID: 31708497 PMC: 6856003. DOI: 10.2183/pjab.95.037.

Role of Hormone-sensitive Lipase in Leptin-Promoted Fat Loss and Glucose Lowering.

Takanashi M, Taira Y, Okazaki S, Takase S, Kimura T, Li C J Atheroscler Thromb. 2017; 24(11):1105-1116.

PMID: 28413180 PMC: 5684476. DOI: 10.5551/jat.39552.

Pleotropic Acute and Chronic Effects of Leptin to Reverse Type 1 Diabetes.

Perry R Postdoc J. 2017; 5(1):3-11.

PMID: 28239611 PMC: 5321081. DOI: 10.14304/surya.jpr.v5n1.2.

Skeletal muscle as a therapeutic target for delaying type 1 diabetic complications.

Coleman S, Rebalka I, Dsouza D, Hawke T World J Diabetes. 2015; 6(17):1323-36.

PMID: 26674848 PMC: 4673386. DOI: 10.4239/wjd.v6.i17.1323.

Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages.

Tate M, Robinson E, Green B, McDermott B, Grieve D Basic Res Cardiol. 2015; 111(1):1.

PMID: 26597728 PMC: 4656717. DOI: 10.1007/s00395-015-0518-1.

References

. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995; 18(11):1415-27. DOI: 10.2337/diacare.18.11.1415. View

Gin H, Messerchmitt C, Brottier E, AUBERTIN J . Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism. 1985; 34(10):923-5. DOI: 10.1016/0026-0495(85)90139-8. View

Sindelar D, Havel P, Seeley R, Wilkinson C, Woods S, Schwartz M . Low plasma leptin levels contribute to diabetic hyperphagia in rats. Diabetes. 1999; 48(6):1275-80. DOI: 10.2337/diabetes.48.6.1275. View

White N, Skor D, Cryer P, Levandoski L, Bier D, Santiago J . Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med. 1983; 308(9):485-91. DOI: 10.1056/NEJM198303033080903. View

Hathout E, Sharkey J, Racine M, Ahn D, Mace J, Saad M . Changes in plasma leptin during the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab. 1999; 84(12):4545-8. DOI: 10.1210/jcem.84.12.6184. View

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J . Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372(6505):425-32. DOI: 10.1038/372425a0. View

Schwartz M, Woods S, Porte Jr D, Seeley R, Baskin D . Central nervous system control of food intake. Nature. 2000; 404(6778):661-71. DOI: 10.1038/35007534. View

Hidaka S, Yoshimatsu H, Kondou S, Tsuruta Y, Oka K, Noguchi H . Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J. 2002; 16(6):509-18. DOI: 10.1096/fj.01-0164com. View

Elmquist J, Maratos-Flier E, Saper C, Flier J . Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci. 1999; 1(6):445-50. DOI: 10.1038/2164. View

10.

Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M . Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes. 1999; 48(9):1822-9. DOI: 10.2337/diabetes.48.9.1822. View

11.

Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H . Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000; 105(9):1243-52. PMC: 315441. DOI: 10.1172/JCI8341. View

12.

Considine R, Sinha M, Heiman M, Kriauciunas A, STEPHENS T, Nyce M . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5):292-5. DOI: 10.1056/NEJM199602013340503. View

13.

Havel P, Liu T, Stanhope K, Stern J, Keen C, Ahren B . Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am J Physiol. 1998; 274(5):R1482-91. DOI: 10.1152/ajpregu.1998.274.5.R1482. View

14.

Marsh D, Hollopeter G, Huszar D, Laufer R, Yagaloff K, Fisher S . Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet. 1999; 21(1):119-22. DOI: 10.1038/5070. View

15.

Havel P, Hahn T, Sindelar D, Baskin D, Dallman M, Weigle D . Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes. 2000; 49(2):244-52. DOI: 10.2337/diabetes.49.2.244. View

16.

Shimomura I, Hammer R, Ikemoto S, Brown M, Goldstein J . Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999; 401(6748):73-6. DOI: 10.1038/43448. View

17.

Maffei M, Halaas J, Ravussin E, Pratley R, Lee G, Zhang Y . Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995; 1(11):1155-61. DOI: 10.1038/nm1195-1155. View

18.

Chinookoswong N, Wang J, Shi Z . Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes. 1999; 48(7):1487-92. DOI: 10.2337/diabetes.48.7.1487. View

19.

. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997; 46(2):271-86. View

20.

Ebihara K, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Satoh N . Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes. 1999; 48(10):2028-33. DOI: 10.2337/diabetes.48.10.2028. View